SARAH MAYER: Open Payments
NPI 1356996110 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$661 in 33 payments from 10 companies in 2025. Trend: 2023 $1,922 · 2024 $901 · 2025 $661
Food & beverage: $577Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $198 |
| ABBVIE INC. | 13 | $161 |
| GENZYME CORPORATION | 5 | $143 |
| Galderma Laboratories, L.P. | 2 | $35 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
| UCB, Inc. | 1 | $23 |
| Amgen Inc. | 1 | $23 |
| Organon LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $17 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $15 |
Products named: TREMFYA, DUPIXENT, SKYRIZI, NEMLUVIO, RINVOQ, Sotyktu, Bimzelx, OTEZLA.
Industry payments across CA — which companies pay providers there.
